Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)
Year: 2021
Session type: E-poster/poster
1Royal Marsden NHS Foundation Trust, 2Other, 3Mount Vernon Cancer Centre, 4University of Pennsylvania, 5Dana-Farber Cancer Institute, 6BC Cancer Agency